8-K: Silexion Therapeutics Faces Nasdaq Delisting Risk, Announces Reverse Stock Split

Silexion Therapeutics received multiple deficiency notices from Nasdaq regarding minimum market value and audit committee composition, and announced a 1-for-9 reverse stock split to regain compliance.

Summary

• Silexion Therapeutics received three deficiency letters from Nasdaq regarding its listing status.
• The first two letters relate to the company's failure to maintain the minimum Market Value of Listed Securities (MVLS) of $50 million and a minimum Market Value of Publicly Held Shares (MVPHS) of $15 million.
• The company has until May 19, 2025, to regain compliance with both market value rules by maintaining the required values for at least 10 consecutive business days.
• The third letter concerns the company's audit committee, which is short one member following a resignation on September 16, 2024.
• Silexion has until the earlier of its next annual general meeting or September 16, 2025, or March 17, 2025, if the annual general meeting is held before that date, to appoint a new member.
• To address these issues, Silexion announced a 1-for-9 reverse stock split, effective after market close on November 27, 2024, with trading on a split-adjusted basis beginning November 29, 2024.
• The reverse split will increase the par value of the ordinary shares from $0.0001 to $0.0009 per share.
• The company may also consider transferring its listing to the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The document highlights significant challenges with Nasdaq listing compliance and the need for a reverse stock split, indicating a negative situation. However, the company expresses confidence in its pipeline and future prospects, preventing a lower score.

Positives

• The company is actively seeking to resolve the Nasdaq listing deficiencies.
• Silexion has a cure period to regain compliance with the Nasdaq listing rules.
• The reverse stock split is intended to help the company regain compliance with Nasdaq's minimum bid price requirement.
• The company has a strong pipeline and is confident in its ability to advance its clinical programs.

Negatives

• Silexion is currently not in compliance with multiple Nasdaq listing rules.
• The company's market value has fallen below the required minimums.
• There is a risk of delisting if the company fails to regain compliance within the allotted timeframes.
• The audit committee has a vacancy that needs to be filled.

Risks

• There is no guarantee that Silexion will regain compliance with Nasdaq listing rules.
• The reverse stock split may not be sufficient to increase the share price and market capitalization.
• The company may face challenges in raising additional capital.
• Delays in clinical trials or regulatory approvals could negatively impact the company's prospects.
• The company faces competition in the RNAi therapy market.

Future Outlook

Silexion intends to regain compliance with Nasdaq listing requirements, potentially through a reverse stock split and by considering a transfer to the Nasdaq Capital Market. The company also plans to advance its clinical programs and deliver value to shareholders.

Management Comments

• Our decision to initiate a reverse share split aligns with Silexion's commitment to maintaining our Nasdaq listing and ensuring a robust foundation for future growth, said Ilan Hadar, Chairman and CEO of Silexion.
• Given our recently reported milestones and strong pipeline, I am confident that we are well-positioned to advance our clinical programs and deliver value to our shareholders and to patients in the future.
• We believe this reverse split will help address the common short-term volatility in our share price that we experienced following our business combination and position us for long-term growth.

Industry Context

The biotech industry often faces challenges related to maintaining listing compliance, especially for companies in the clinical stage. Reverse stock splits are a common strategy to address low share prices and market capitalization issues. Silexion's focus on RNAi therapies for KRAS-driven cancers places it in a competitive but promising area of oncology research.

Comparison to Industry Standards

• Many clinical-stage biotech companies face similar challenges with maintaining Nasdaq listing requirements, particularly regarding minimum market capitalization and share price.
• Companies like Cellectar Biosciences (CLRB) and Agenus (AGEN) have also used reverse stock splits to regain compliance with Nasdaq listing rules.
• The 180-day grace period provided by Nasdaq for regaining compliance is standard practice.
• The requirement for a minimum number of independent directors on the audit committee is a common corporate governance standard.

Management Changes

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own due to the reverse stock split.
• The reverse stock split is intended to help the company maintain its Nasdaq listing, which is important for shareholder value.
• The company's ability to raise capital may be affected by its listing status.
• Employees may be impacted by the company's financial performance and strategic decisions.
• Customers and partners may be affected by the company's ability to continue its research and development programs.

Next Steps

• Silexion will implement a 1-for-9 reverse stock split.
• The company will seek to regain compliance with Nasdaq listing rules.
• Silexion will continue to seek an additional independent director for the audit committee.
• The company may consider transferring its listing to the Nasdaq Capital Market.
• Silexion will continue to advance its clinical programs.

Key Dates

Keywords

Nasdaq, delisting, reverse stock split, market value, audit committee, compliance, RNAi, biotechnology, KRAS, oncology